Brexpiprazole
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09128 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 23 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | dysthymic disorder | KG + DL |
| 2 | benign paroxysmal torticollis of infancy | KG + DL |
| 3 | agoraphobia | KG + DL |
| 4 | neurotic disorder | KG + DL |
| 5 | neurotic depression | KG + DL |
| 6 | melancholia | KG + DL |
| 7 | Keppen-Lubinsky syndrome | KG + DL |
| 8 | Ohdo syndrome and variants | KG + DL |
| 9 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 10 | congenital isolated adrenocorticotropic hormone deficiency (disease) | KG + DL |
| 11 | vitamin B12-responsive methylmalonic acidemia | KG + DL |
| 12 | autosomal dominant slowed nerve conduction velocity | KG + DL |
| 13 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 14 | hydranencephaly (disease) | KG + DL |
| 15 | syndromic myopia | KG + DL |
| 16 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 17 | blepharophimosis - intellectual disability syndrome, Ohdo type | KG + DL |
| 18 | childhood apraxia of speech | KG + DL |
| 19 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 20 | myopia X-linked | KG + DL |
| 21 | atypical glycine encephalopathy | KG + DL |
| 22 | myopia 26, X-linked, female-limited | KG + DL |
| 23 | surfactant metabolism dysfunction, pulmonary | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.